The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.

Cordis US Corp.100 enrolled

Overview

The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as compared to the uncoated Bx VELOCITY™ balloon-expandable stent. Both stents are mounted on the Raptor® Stent Delivery Systems. The secondary objective is to assess cost-effectiveness expressed in incremental cost/life year gained or cost/quality adjusted life year gained at different time points (8 months, 1 year, 3 and 5 years).

This is a multicenter ,prospective, randomized double blind study. This study has a 2-arm design assessing the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent to the uncoated Bx VELOCITY™ stent, both mounted on Raptor® Stent Delivery Systems. A total of 100 patients will be entered in the study and will be randomized on a 1:1 basis. Patients who meet the eligibility criteria will be either randomized to Treatment A or Treatment B. Neither the investigator nor the patient will know which stent will be implanted. Patients will be followed at 30 days, 6, 9, and 12 months, and at 2, 3, 4 and 5 years post-procedure, with all patients undergoing repeat angiography at 8 months. Additionally, medical costs associated with the index hospitalization and length of stay, and repeat hospitalizations and costs associated with other relevant medical resource use during the 5 years follow-up period will be collected and analyzed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

100

Conditions

Coronary Artery Disease

Interventions

drug-eluting stentDEVICE

sirolimus-coated Bx VELOCITY Balloon-Expandable Stent

bare-metal stentDEVICE

un-coated Bx VELOCITY Stent

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II) OR patients with documented silent ischemia; * Single treatment of de novo lesion in a major coronary artery in patients with single or multi-vessel disease; patients with multiple lesions can be included only if the other lesions do not require treatment; * Target vessel diameter at the lesion site is \>=2.50mm and \<=3.0mm in diameter (visual estimate); * Target lesion is \>=15mm and \<=32mm in length (visual estimate); * Target lesion stenosis is \>50% and \<100% (visual estimate); Exclusion Criteria: * Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment; * Has unstable angina classified as Braunwald III B or C and A I-II-III, or is having a peri infarction; * Unprotected left main coronary disease with \>=50% stenosis; * Significant (\>50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff; * Have an ostial target lesion; * Angiographic evidence of thrombus within target lesion; * Heavily calcified lesion which cannot be successfully predilated; * Documented left ventricular ejection fraction \<=25%.

Outcomes

Primary Outcomes

in-stent minimum lumen diameter (MLD)

Time frame: 8 months

Secondary Outcomes

composite of Major Adverse Cardiac Events defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization

Time frame: 30 days and 6, 9, and 12 months, and 2, 3, 4 and 5 years

angiographic binary restenosis (³50% diameter stenosis)

Time frame: 8 months

in-lesion MLD

Time frame: 8 months

target lesion revascularization

Time frame: 9 months

target vessel revascularization

Time frame: 9 months

target vessel failure defined as cardiac death, myocardial infarction, or target vessel revascularization

Time frame: 9 months

procedure success defined as achievement of a final diameter stenosis of <50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion

Time frame: up to hospital discharge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.